Revolution Medicines, Inc.
NASDAQRevolution Medicines heads into its June 18 Q1 results with the Street's conviction rising and short sellers quietly rebuilding positions after a month of covering. The analyst story is the dominant theme this week. Targets have moved sharply higher across the board, with Evercore ISI lifting its price objective to $220 from $200 just today — the most aggressive call in the current…
RVMD cost to borrow surges 298% in one week to 0.50%, reflecting tightening short availability as stock climbs 47% in April.
Snapshot as of 22 Jun 2026
Revolution Medicines heads into its June 18 Q1 results with the Street's conviction rising and short sellers quietly rebuilding positions after a month of covering. The analyst story is the dominant theme this week.…
Revolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a…
Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RVMD — free to start on ORTEX.
Sign up for free →Open RVMD on ORTEX